A novel in vitro model system for studying the action of ara-C

被引:12
|
作者
Hickey, R
Ross, D
Ross, D
Cuddy, D
Malkas, L
机构
[1] UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201
[2] UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201
[3] UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21201
[4] BALTIMORE VET MED CTR,BALTIMORE,MD
[5] UNIV MARYLAND,CTR CANC,DIV DEV THERAPEUT,BALTIMORE,MD 21201
[6] UNIV BALTIMORE,MOLEC & CELLULAR BIOL PROGRAM,BALTIMORE,MD 21201
关键词
cytosine arabinoside; anticancer drugs; mammalian cells; multiprotein DNA replication complex; in vitro model system;
D O I
10.1007/s002800050496
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) has proven to be one of the most effective agents available for the treatment of acute leukemia. While ara-C has been implicated as a potent inhibitor of mammalian cell DNA replication, the specific mechanism by which ara-C kills cells is not known. In this report we describe the development of an in vitro model system to study the molecular mechanism of ara-CMP incorporation into DNA. This model system makes use of a recently described human cell multiprotein DNA replication complex (MRC) that is competent to replicate DNA in vitro. The MRC can successfully incorporate ara-CMP into replicating DNA at internucleotide positions. These results are similar to those described for studies using intact cells. This MRC-driven in vitro replication system may therefore serve as a powerful model for the study of anticancer agents that directly affect human cell DNA synthesis.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 50 条
  • [1] AN IN VITRO KINETIC MODEL FOR ACTION OF ARA C
    KARON, M
    SHIRAKAW.S
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1968, 9 (MAR): : 35 - &
  • [2] CELLULAR MODEL FOR ACTION 1-BETA-D ARABINOFURANOSYLCYTOSINE (ARA-C)
    EDELSTEIN, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1975, 16 (MAR): : 12 - 12
  • [3] Cytosine arabinoside (Ara-C) syndrome and Ara-C induced pericarditis
    Yamada, T
    Tsurumi, H
    Sawada, M
    Hara, T
    Moriwaki, H
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 334 - 334
  • [4] In vitro leukemia cell models of Ara-C resistance
    Funato, T
    Satou, J
    Nishiyama, Y
    Fujimaki, S
    Miura, T
    Kaku, M
    Sasaki, T
    LEUKEMIA RESEARCH, 2000, 24 (06) : 535 - 541
  • [5] In vitro and in vivo evaluation of L-valyl-ara-C for the oral delivery of ara-C
    Cheon, Eun-Pa
    Jin, Ming Ji
    Han, Hyo-Kyung
    DRUG METABOLISM REVIEWS, 2006, 38 : 72 - 73
  • [6] ARA-C VASCULITIS
    HIPPE, E
    JONSSON, V
    SCHRODER, HD
    JENSEN, TS
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1988, 41 (01) : 96 - 96
  • [7] Cytosine arabinoside (Ara-C) syndrome - especially Ara-C induced pericarditis
    Yamada, T
    Tsurumi, H
    Sawada, M
    Hara, T
    Moriwaki, H
    BLOOD, 1997, 90 (10) : 3861 - 3861
  • [8] SEVERAL MECHANISMS OF ACTION INVOLVED IN CELLULAR TOXICITY OF ARA-C
    MARQUET, J
    ZITTOUN, J
    DAVID, JC
    ZITTOUN, R
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1987, 29 (06): : 433 - 433
  • [9] Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML
    Abraham, Ajay
    Yaratharajan, Savitha
    Jayavelu, Ashok Kumar
    Velayudhan, Shaji R.
    Ahmed, Rayaz
    Abraham, Aby
    George, Biju
    Chandy, Mammen
    Srivastava, Alok
    Mathews, Vikram
    Balasubramanian, Poonkuzhali
    BLOOD, 2011, 118 (21) : 1486 - 1486
  • [10] ARA-C INCORPORATION INTO DNA
    KUFE, DW
    SPRIGGS, DR
    BLOOD, 1985, 65 (01) : 246 - 246